FBLG vs. EDIT, GLSI, TARA, SCPH, LYEL, TNXP, FATE, THTX, ALEC, and ACOG
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Editas Medicine (EDIT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), Lyell Immunopharma (LYEL), Tonix Pharmaceuticals (TNXP), Fate Therapeutics (FATE), Theratechnologies (THTX), Alector (ALEC), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.
FibroBiologics vs.
Editas Medicine (NASDAQ:EDIT) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.
FibroBiologics has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. FibroBiologics' return on equity of 0.00% beat Editas Medicine's return on equity.
In the previous week, Editas Medicine had 7 more articles in the media than FibroBiologics. MarketBeat recorded 13 mentions for Editas Medicine and 6 mentions for FibroBiologics. Editas Medicine's average media sentiment score of 0.65 beat FibroBiologics' score of -0.24 indicating that Editas Medicine is being referred to more favorably in the media.
FibroBiologics has lower revenue, but higher earnings than Editas Medicine. FibroBiologics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Editas Medicine received 303 more outperform votes than FibroBiologics when rated by MarketBeat users. However, 100.00% of users gave FibroBiologics an outperform vote while only 53.46% of users gave Editas Medicine an outperform vote.
Editas Medicine presently has a consensus target price of $5.36, suggesting a potential upside of 257.58%. FibroBiologics has a consensus target price of $13.00, suggesting a potential upside of 1,323.10%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Editas Medicine.
Editas Medicine has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, FibroBiologics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.
71.9% of Editas Medicine shares are owned by institutional investors. 2.1% of Editas Medicine shares are owned by insiders. Comparatively, 20.0% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Editas Medicine and FibroBiologics tied by winning 9 of the 18 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
This page (NASDAQ:FBLG) was last updated on 5/21/2025 by MarketBeat.com Staff
